The FierceBiotechIT website reports that GlaxoSmithKline has committed to provide researchers with unmatched access to patient-level data from its clinical trials–including studies that failed. The move is among several steps the London-based drug giant announced today to promote open innovation and collaboration with external groups. In adding access to the patient-level data from trials, GSK is taking its open innovation drive much further than any of its pharma company peers.
Click here to read the full article.
